Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) have received an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $5.17.

SGMO has been the subject of several recent research reports. Wells Fargo & Company decreased their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research report on Tuesday, December 31st. Barclays raised their price target on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Sangamo Therapeutics in a research report on Monday. Truist Financial decreased their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Finally, StockNews.com cut shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th.

Institutional Investors Weigh In On Sangamo Therapeutics

Institutional investors have recently modified their holdings of the company. Shelton Wealth Management LLC acquired a new stake in Sangamo Therapeutics during the 4th quarter worth $29,000. Sageworth Trust Co acquired a new stake in Sangamo Therapeutics during the 4th quarter worth $61,000. Meritage Portfolio Management raised its stake in Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 6,740 shares in the last quarter. XTX Topco Ltd raised its stake in Sangamo Therapeutics by 167.8% during the 3rd quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 64,981 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in Sangamo Therapeutics by 55.4% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 38,850 shares in the last quarter. 56.93% of the stock is owned by hedge funds and other institutional investors.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock opened at $1.13 on Friday. Sangamo Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.18. The firm has a 50 day moving average price of $1.76 and a 200 day moving average price of $1.33. The company has a market capitalization of $235.77 million, a PE ratio of -1.51 and a beta of 1.29.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The firm had revenue of $49.41 million during the quarter, compared to the consensus estimate of $26.55 million. During the same quarter last year, the firm earned ($0.34) EPS. As a group, equities research analysts forecast that Sangamo Therapeutics will post -0.47 earnings per share for the current year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.